Fig. 2From: Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancera: Cost-effectiveness pictured with two groups. Two groups were analyzed: group SCRT and group LCCRT patients with advanced resectable rectal cancer. b: Cost-effectiveness acceptability curves for SCRT and LCCRT strategies. Each curve shows the probability that the ICER for each treatment falls within a given willingness-to-pay threshold. QALM, Quality-adjusted life year; US$, United States dollarsBack to article page